Evidence map›Paper›PMID 32153795›Full record

ArticleLupus science & medicine2020

Serum uric acid is associated with damage in patients with systemic lupus erythematosus.

Claudia Elera-Fitzcarrald, Cristina Reátegui-Sokolova, Rocio Violeta Gamboa-Cardenas, Mariela Medina, Francisco Zevallos, Victor Román Pimentel-Quiroz, Jorge Mariano Cucho-Venegas, José Alfaro-Lozano, Zoila Rodriguez-Bellido, Cesar Augusto Pastor-Asurza and 3 more

Abstract read
In one paragraph

Article in Lupus science & medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Claudia Elera-FitzcarraldSchool of Medicine, Universidad Científica del Sur, Lima, Peru.ORCID 0000-0001-7271-2523
Cristina Reátegui-SokolovaRheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.
Rocio Violeta Gamboa-CardenasRheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.
Mariela MedinaRheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.
Francisco ZevallosRheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.
Victor Román Pimentel-QuirozRheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.ORCID 0000-0002-3638-7054
Jorge Mariano Cucho-VenegasRheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.
José Alfaro-LozanoRheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.
Zoila Rodriguez-BellidoRheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.
Cesar Augusto Pastor-AsurzaRheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.
Risto Alfredo Perich-CamposRheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.
Graciela S AlarcónDepartment of Medicine, Division of Clinical Immunology and Rheumatology, School of Medicine, The University of Alabama, Birmingham, Alabama, USA.
Manuel Francisco Ugarte-GilSchool of Medicine, Universidad Científica del Sur, Lima, Peru.ORCID 0000-0003-1728-1999

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Serum uric acid levels have been reported as predictors of cardiovascular, pulmonary, neurological and renal morbidity in patients with SLE. However, their role in cumulative global damage in these patients has not yet been determined. Objective: To determine whether serum uric acid levels are associated with new damage in patients with SLE. Methods: This is a longitudinal study of patients with SLE from the Almenara Lupus Cohort, which began in 2012. At each visit, demographic and clinical characteristics were evaluated, such as activity (Systemic Lupus Erythematosus Disease Activity Index-2K or SLEDAI-2K) and cumulative damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index or SDI). Treatment (glucocorticoids, immunosuppressive drugs and antimalarials) was also recorded. Univariable and multivariable Cox regression models were used to determine the impact of serum uric acid levels on the risk of new damage. Results: We evaluated 237 patients, with a mean age (SD) at diagnosis of 35.9 (13.1) years; 220 patients (92.8%) were women, and the duration of the disease was 7.3 (6.6) years. The mean SLEDAI-2K and SDI scores were 5.1 (4.2) and 0.9 (1.3), respectively. Serum uric acid level was 4.5 (1.4) mg/dL. Follow-up time was 3.1 (1.3) years, and 112 (47.3%) patients accrued damage during follow-up. In univariable and multivariable analyses, serum uric acid levels were associated with new damage (HR=1.141 (95% CI 1.016 to 1.282), p=0.026; HR=1.189 (95% CI 1.025 to 1.378), p=0.022, respectively). Conclusion: Higher serum uric acid levels are associated with global damage in patients with SLE.

Indexed as

AdultAntimalarialsBiomarkersComorbidityDisease ProgressionFemaleFollow-Up StudiesGlucocorticoidsHumansImmunosuppressive AgentsLongitudinal StudiesLupus Erythematosus, SystemicMaleMiddle AgedPeruSeverity of Illness IndexAntimalarialsBiomarkersGlucocorticoidsImmunosuppressive AgentsUric Acidautoimmune diseasesautoimmunitysystemic lupus erythematosus

Identifiers

PMID32153795
PMCPMC7046960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.